WO2007123131A1 - Système d'ionophorèse - Google Patents

Système d'ionophorèse Download PDF

Info

Publication number
WO2007123131A1
WO2007123131A1 PCT/JP2007/058362 JP2007058362W WO2007123131A1 WO 2007123131 A1 WO2007123131 A1 WO 2007123131A1 JP 2007058362 W JP2007058362 W JP 2007058362W WO 2007123131 A1 WO2007123131 A1 WO 2007123131A1
Authority
WO
WIPO (PCT)
Prior art keywords
working
drug
ion
electrode structure
viscous liquid
Prior art date
Application number
PCT/JP2007/058362
Other languages
English (en)
Japanese (ja)
Inventor
Yuriko Watanabe
Mitsugu Yamauchi
Original Assignee
Tti Ellebeau, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tti Ellebeau, Inc. filed Critical Tti Ellebeau, Inc.
Priority to JP2008512122A priority Critical patent/JPWO2007123131A1/ja
Publication of WO2007123131A1 publication Critical patent/WO2007123131A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0444—Membrane

Definitions

  • the present invention relates to an iontophoresis system including an iontophoresis device for administering drug ions to a living body by applying a voltage, and in particular, the skin of the living body and the iontophoresis device.
  • the present invention relates to an iontophoresis system that can easily improve the adhesion of an ion-selective membrane and deliver drug ions evenly.
  • a working electrode structure As an iontophoresis device for administering drug ions to a living body by applying a voltage, as described in WO03037425 (Patent Document 1), a working electrode structure and a non-action Some have side electrode structures that allow medicinal ions to be administered to the skin and mucous membranes from the ion exchange membrane of the working electrode structure.
  • the working electrode structure in the iontophoresis device described in Patent Document 1 includes, from the contact side with the skin or mucous membrane, an ion exchange membrane, a chemical solution holding unit, an ion exchange membrane, an electrolyte holding unit, The working side electrodes are stacked in this order.
  • the non-working side electrode structure is formed by laminating an ion exchange membrane, an electrolytic solution holding unit, an ion exchange membrane, an electrolytic solution holding unit, and a non-working side electrode in this order from the contact side with the skin or mucous membrane. Configured.
  • the present invention can easily deliver drug ions to the skin by simply interposing a contact liquid, eliminating the gap between the ion-selective membrane such as an ion exchange membrane and the skin and improving adhesion.
  • the problem to be solved is to provide technologies that can be used.
  • the present invention comprises a DC power supply, a working electrode structure connected to one of an anode and a cathode of the DC power supply, and a non-working electrode structure connected to the other, and the working electrode
  • An iontophoresis device for administering a drug ion held in a structure to a living body by a voltage from the DC power source, wherein the working electrode structure has the same kind of polarity as the drug ion.
  • a working electrode connected to an anode or a cathode; a drug solution holding unit electrically connected to the working side electrode for holding a drug to be the drug ion; and electrically connected to the drug solution holding unit;
  • An iontophoresis device having at least a working ion selective membrane that selectively allows the same kind of ions as drug ions to pass through, and a living body side of the working ion selective membrane of the iontophoresis device
  • the order to cover characterized by comprising a release liner viscous liquid holding portion is provided, the Onto Foret over cis system ⁇ Koyori is obtained by solving the above problems.
  • the present invention is also composed of a DC power source, a working side electrode structure connected to one of an anode and a cathode of the DC power source and a non-working side electrode structure connected to the other, An iontophoresis device for administering drug ions held in a working electrode structure to a living body by a voltage from the DC power source, wherein the non-working electrode structure is opposite to the drug ions.
  • a non-working-side electrode connected to the anode or cathode, an electrolyte-holding unit electrically connected to the working-side electrode and holding the electrolyte, and an electrical connection with the electrolyte-holding unit
  • An iontophoresis device having at least a non-working side ion selective membrane connected and selectively allowing ions opposite to the drug ions to pass therethrough, and non-working side ion selection of the iontophoresis device
  • the biological side of the membrane For bars, and release liner viscous liquid holding portion is provided by I O cement Foret over cis system comprising the one in which the above-mentioned problems are eliminated.
  • the viscous liquid holding portion may include a continuous foamed body such as a sponge disposed in a recess of the release liner.
  • the viscous liquid may be a mixture of water and a water-soluble polymer.
  • the viscous liquid may include the same drug as the drug in the drug holding unit or the same electrolytic solution as the electrolytic solution in the electrolytic solution holding unit.
  • the viscous liquid is retained using the release liner having the viscous liquid retaining portion, so that the viscous liquid can be easily attached to the ion selective membrane. It improves the adhesion between the selective membrane and the skin and allows sufficient delivery of drug ions to the skin.
  • FIG. 1 is an exploded perspective view showing an iontophoresis system according to an embodiment of the present invention.
  • FIG. 2 is a working side electrode and a non-working side in an iontophoresis device of the iontophoresis system. Plan view showing enlarged electrode part
  • FIG.5 Sectional view showing the assembled state of the iontophoresis system
  • FIG. 6 Cross-sectional view showing the state of wearing the release liner of the iontophoresis system
  • FIG. 7 Cross-sectional view showing the wearing state of the iontophoresis device on the skin
  • An iontophoresis device 10 constituting the iontophoresis system is connected to a DC power source 12, a working electrode structure 20 connected to one of an anode and a cathode of the DC power source 12, and the other.
  • the non-working side electrode structure 40 is configured to administer drug ions held in the working side electrode structure 20 to the living body by the voltage from the DC power source 12.
  • the working electrode structure 20 and the non-working electrode structure 40 are formed by superposing constituent members such as a chemical solution holding unit, and each of them is a base that also has a resin sheet force. It is configured to be sandwiched between the end support 14 and the intermediate support 16 or housed in a through hole formed in the intermediate support 16 and the tip support 18.
  • the proximal support 14 and the intermediate support 16 are the same size, and the distal support 18 is formed larger than these. It is.
  • the base end support body 14, the intermediate support body 16 and the front end support body 18 are all provided with adhesive layers 14A, 16A and 18A on the lower surface in FIG.
  • the adhesive layer 18A of the tip support 18 is made to adhere to the skin or mucous membrane!
  • the intermediate support 16 is a sheet-like member that constitutes a part of the working electrode structure 20 and a part of the non-working electrode structure 40.
  • the tip support 18 is a sheet-like member that constitutes a part of the working electrode structure 20 and a part of the non-working electrode structure 40.
  • the working electrode structure 20 includes a working electrode 24 having the same polarity as the drug ions in the DC power source 12 and connected to the anode or the cathode, and a separator 26 disposed in front of the working electrode 24. And an intermediate ion-selective membrane 28 that is disposed in front of the separator 26 and selectively passes ions having opposite signs to the drug ions, and is disposed on the front surface of the intermediate ion-selective membrane 28 to become drug ions.
  • a drug solution holding unit 30 that holds a drug and a working ion selective membrane 32 that is disposed in front of the drug solution holding unit 30 and selectively passes the same type of ions as the drug ions are stacked in this order. Has been.
  • the working side electrode 24 is connected to the DC power source 12, and the working side current collector 24A made of a material containing a film-like carbon formed on the front surface of the resin sheet 36 by printing, and this action It is composed of a working side polarizable electrode 24B arranged in electrical connection with the front surface of the side current collector 24A.
  • Electrode connected includes not only the case of direct connection but also the case of connection via a conductive material such as a conductive adhesive (the same applies hereinafter).
  • the intermediate support 16 also has a grease material force having a thickness substantially equal to that of the working-side polarizable electrode 24B, and the working-side intermediate through having substantially the same shape as the outer shape of the working-side polarizable electrode 24B in plan view.
  • the working side polarizable electrode 24B has a hole 21A and is accommodated in the working side intermediate through hole 21A.
  • the tip support 18 also has a resin material force having a thickness substantially equal to that of the chemical solution holding part 30, and the working tip through-hole 22A having substantially the same shape as the planar shape of the working polarizable electrode 24B.
  • the drug solution holding part 30 is accommodated in the working side front end through hole 22A.
  • the non-working side electrode structure 40 includes a non-working side electrode 44 connected to an anode or a cathode having a polarity opposite to that of the drug ion in the DC power source 12 from the base support 14 side.
  • Electrode-side electrolyte holder 46 that holds the electrolyte
  • the tip-side electrolyte holder 48 that holds the same electrolyte
  • ions with the opposite sign to the drug ions A non-working side ion selective membrane 50 that is allowed to pass therethrough is laminated in this order.
  • the non-working electrode 44 is a non-working material made of carbon-containing material printed on the front surface of the resin sheet 36 and spaced from the working current collector 24A of the working electrode 24. It is composed of a side current collector 44A and a non-working side polarizable electrode 44B arranged in electrical connection with the front surface of the non-working side current collector 44A.
  • the non-working-side polarizable electrode 44B has the same thickness as the intermediate support 16, and is accommodated in the non-working-side intermediate through hole 41A formed therein.
  • the tip side electrolyte solution holding part 48 has the same thickness as the tip end support 18 and is accommodated in a non-working side tip through hole 42 A formed in the tip support 18.
  • the through holes 22A, 21A, 41A, 42A are all circular, and further, the working side electrode 24, the separator 26, the intermediate ion selective membrane 28, the chemical solution holding unit 30, and the working side ion selection.
  • the membrane 32 also has a circular membrane! /, Which is a sheet! /.
  • the non-working side electrode 44, the electrode side electrolyte holding unit 46, the tip side electrolyte holding unit 48, and the non-working side ion selective membrane 50 are also formed into a circular membrane or a sheet. .
  • the resin sheet 36 includes a working current collector 24A in the working electrode 24 and a non-working current collector 44A in the non-working electrode 44.
  • a working side conductor 19A and a non-working side conductor 19B made of a material containing carbon formed by continuous printing in a film form are connected to each other.
  • These working-side conducting wire 19A and non-working-side conducting wire 19B are connected to the DC power source 12 via a connector 19C at their tips.
  • an insulating film 19D having a polyimide film force, for example, is adhered to the side surfaces of the working side conductor 19A and the non-working side conductor 19B opposite to the resin sheet 36.
  • the insulating film 19D has a length that covers a range of the working-side conductor 19A and the non-working-side conductor 19B in contact with the resin sheet 36 and a certain range of a protruding portion from the resin sheet 36. In this embodiment, as shown in FIGS.
  • each circular member is arranged in the thickness direction in each of the working electrode structure 20 and the non-working electrode structure 40.
  • the iontophoresis device 10 is configured by overlapping and integrating, and as shown in FIG. 5, an iontophoresis system is configured by attaching a later-described release liner 58.
  • Reference numeral 56 in FIG. 4 denotes an adhesive, and this adhesive 56 is disposed across an intermediate portion between the active and non-active current collectors 24A and 44A in the insulating film 19D, Rum 19D and the intermediate support 16 are bonded, and the insulating film 19D and the intermediate support 16 are separated from the working side and the non-working side.
  • a release liner 58 provided with recesses 60 and 62 at positions corresponding to the working side ion selective membrane 32 and the non-working side ion selective membrane 50, respectively, can be peeled off.
  • a release liner 58 provided with recesses 60 and 62 at positions corresponding to the working side ion selective membrane 32 and the non-working side ion selective membrane 50, respectively, can be peeled off.
  • sponge 64 and 66 forces soaked with viscous liquid are respectively held.
  • the chemical solution holding unit 30 is configured by impregnating a PP (polypropylene) non-woven fabric with a viscous liquid containing a drug.
  • the drug impregnated in the drug solution holding unit 30 contains positive or negative ions (drugs that dissociate into drug ions (including drug precursors)) by dissolving in a solvent such as water.
  • positive or negative ions drugs that dissociate medicinal components into positive ions
  • examples of drugs that dissociate medicinal components into positive ions include lidocaine hydrochloride, which is an anesthetic, and morphine hydrochloride, which is an anesthetic, and vitamins that can be used to dissociate medicinal ingredients into anions. Examples include ascorbic acid and the like.
  • the electrode side electrolyte solution holding part 46 in the non-working side electrode structure 40 is made of a PP non-woven fabric with an electrolyte solution.
  • the tip side electrolyte solution holding part 48 is also made by impregnating a PP liquid nonwoven with a viscous liquid containing the same electrolyte solution.
  • the electrolyte used for the electrode side electrolyte holding part 46 and the tip side electrolyte holding part 48 is an electrolytic solution.
  • the main component of this electrolyte is an electrolyte that is more susceptible to oxidation or reduction than water electrolysis (oxidation at the anode and reduction at the cathode), such as ascorbic acid (vitamin C) and sodium ascorbate.
  • vitamin C ascorbic acid
  • the viscous liquid containing the drug or the electrolyte impregnated in the chemical solution holding unit 30 or the electrolyte solution holding units 46 and 48 is, for example, water (ion exchange water), HPC (hydroxypropyl cellulose) ( For example, Nippon Soda Co., Ltd.'s H-Type), or Metrose (for example, 9 OSH from Shin-Etsu Chemical Co., Ltd.) that has been treated with water-insoluble cellulose to form a water-soluble polymer. It can be produced by mixing 2% by mass or more of a thickener such as 10000SR).
  • a thickener such as 10000SR
  • the viscous liquid contained in the sponges 64 and 66 is, for example, water (ion exchange water), HPC (hydroxypropylcellulose) (for example, H-Type of Nippon Soda Co., Ltd.), or water. Manufactured by mixing 2% by mass or more of a thickener such as Metroise (for example, 90SH-10000SR from Shin-Etsu Chemical Co., Ltd.), which is a water-soluble polymer by chemically treating insoluble cellulose. Can do.
  • the viscous liquid contained in sponge 64 can be produced by calcining HPC with the chemical solution in water.
  • the viscous liquid contained in sponge 66 is obtained by adding HPC to the electrolyte solution in water. May be manufactured.
  • the method for producing the viscous liquid is not limited to the above method.
  • the viscous liquid may be a solution having a viscosity obtained by uniformly dissolving the water-soluble polymer in water.
  • Viscous liquid containing chemical solution is acceptable as long as it contains chemical solution, water, and water-soluble polymer.
  • Viscous liquid containing electrolyte solution is that containing electrolytic solution, water, and water-soluble polymer. That's fine.
  • the water-soluble polymer functions as a thickener. An appropriate amount of a water-soluble polymer is blended to adjust the viscosity of the electrolytic solution or chemical solution.
  • the water-soluble polymer used here is not particularly limited as long as the polymer is soluble in water.
  • Water-soluble polymers are classified into natural polymers, semi-synthetic polymers, and synthetic polymers. Can be any.
  • the water-soluble polymer can be layered into a ionic water-soluble polymer, a cationic water-soluble polymer, and a nonionic polymer according to electrical properties.
  • a ionic water-soluble polymer a cationic water-soluble polymer
  • a nonionic polymer a nonionic polymer according to electrical properties.
  • Use of nonionic water-soluble polymer is preferable to prevent gelling caused by pH change.
  • water-soluble polymers include cellulose polymers, polysaccharide polymers, water-soluble proteins, starch polymers, alginic acid polymers, acrylic polymers, vinyl polymers, and glycols. Based polymers and the like. In the present invention, it is preferable to use at least one selected from these water-soluble polymer forces.
  • Cellulosic polymers include methylcellulose (nonionic), ethylcellulose (nonionic), carboxymethylcellulose (aion), hydroxyethylcellulose (nonionic), hydroxypropylcellulose ( Nonionic), hydroxypropyl methylcellulose (nonionic), nitrocellulose (nonionic), cationized cellulose (cationic) and the like.
  • Polysaccharide polymers include gum arabic (a-on), carrageenan (a-on), guar gum (non-ionic), locust bean gum (non-ionic), pectin (non-ionic) ), Tragacanth, corn starch (non-ionic), xanthan gum (non-ionic), dextrin (non-ionic), cationic guagua gum (cationic), sodium hyaluronate (non-ionic), sodium chondroitin sulfate A, sodium chondroitin sulfate B, sodium chondroitin sulfate C (all of which are on), chitosan, chitosan derivatives, chitin, chitin derivatives and the like.
  • water-soluble protein examples include gelatin, elastin, collagen, BSA and the like.
  • starch-based polymer examples include phosphate starch.
  • alginic acid-based polymer examples include sodium alginate (a-on type), propylene glycol alginate (nonionic), and the like.
  • Acrylic polymers include sodium polyacrylate (a-on), carboxyvinyl polymer (non-ionic), polyacrylamide (non-ionic), and acrylamide 'atrely Copolymer (anionic) and the like.
  • bur polymer examples include polyvinyl pyrrolidone (nonionic), polybulu alcohol.
  • Nonionic vinylpyrrolidone vinylacetic acid copolymer (PVPZVA copolymer) (nonionic) and the like.
  • glycol polymers include polyethylene glycol (with a molecular weight of 20,000 to 5,000,000) (both are nonionic), a copolymer of polypropylene glycol and polyethylene glycol (PEO—PPO—PEO, Pluronic). , Proxamer) and the like.
  • hydroxyalkyl celluloses such as hydroxychetinoresenorelose, hydroxypropinoresenorelose, hydroxypropinoremethinocellulose and the like are more preferably used. Is particularly preferred.
  • Hydroxyalkyl cellulose can be produced by a known method, for example, by reacting an alkali cellulose with an alkylene oxide such as ethylene oxide or propylene oxide. Moreover, what was acquired as a commercial item can also be used as it is.
  • the amount of the water-soluble polymer to be used is not particularly limited as long as the water-soluble polymer to be used is in a range that can be uniformly dissolved in water. By increasing or decreasing the amount of the water-soluble polymer used within the range in which the water-soluble polymer used is uniformly dissolved in water, the viscosity of the resulting viscous liquid can be brought to a desired value.
  • the amount of the water-soluble polymer used is usually 0.1 to 50% by weight, preferably 1 to L0% by weight, more preferably 2 to 5% by weight, based on the whole viscous liquid.
  • the viscosity of the resulting viscous liquid is usually 0.05 Pa's or more.
  • the working-side polarizable electrode 24B in the working-side electrode 24 and the non-working-side polarizable electrode 44B in the non-working-side electrode 44 are both formed of activated carbon, preferably carbon fiber or carbon fiber paper! It is composed mainly of a conductive base material.
  • the layer may be formed by combining cloth and felt made of activated carbon fiber.
  • a layer in which activated carbon is dispersed in a binder polymer may be laminated on the conductive substrate.
  • the activated charcoal may have a specific surface area of 10m 2 Zg or more.
  • the working side polarizable electrode 24B has the same drug as the drug held in the drug solution holding unit 30.
  • the non-working-side polarizable electrode 44B is impregnated with a viscous liquid containing the same electrolytic solution as the electrolytic solution held in the electrode-side electrolytic solution holding part 46.
  • Both the working side current collector 24A in the working side electrode 24 and the non-working side current collector 44A in the non-working side electrode 44 are printed by mixing a PET (polyethylene terephthalate) material with carbon and an adhesive. Formed.
  • PET polyethylene terephthalate
  • the working current collector 24A and the non-working current collector 44A may be made of conductive materials such as gold, platinum, silver, copper, and zinc, in addition to carbon as long as they have conductivity. Other metals may be used. In addition, a conductive material itself such as carbon or gold that is printed can be used as the current collector. The same applies to the material of the working conductor 19A and the non-working conductor 19B.
  • the separator 26 is obtained by impregnating a PP non-woven fabric with a viscous liquid containing the same drug as the drug held in the drug solution holding unit 30, and includes the working side polarizable electrode 24B and the intermediate ion selective membrane. By interposing between the two, physical contact between the two is prevented.
  • the working-side ion-selective membrane 32 is configured to include an ion-exchange resin into which an ion-exchange group has been introduced so that ions having the same sign as drug ions can be selectively passed therethrough. That is, the working side ion-selective membrane 32 contains a cation exchange resin when dissociating into a chemical force S cation of the chemical solution holding unit 30, and contains an anion exchange resin when dissociating into a cation.
  • the intermediate ion selective membrane 28 is configured to contain an ion exchange resin into which an ion exchange group has been introduced so as to selectively pass ions having the opposite signs to the drug ions. That is, the intermediate ion-selective membrane 28 contains anion exchange resin when dissociating into the chemical force S cation of the chemical solution holding unit 30, and contains cation exchange resin when dissociating into the cation.
  • the non-working side ion-selective membrane 50 is an ion-exchange resin in which an ion-exchange group has been introduced so as to selectively pass drug ions and ions having opposite signs. It is comprised including. That is, the non-working side ion selective membrane 50 contains an anion exchange resin when dissociating into the chemical force S cation of the chemical solution holding unit 30 and contains a cation exchange resin when dissociating into the cation. Out.
  • Examples of the cation exchange resin include a three-dimensional network structure such as a polystyrene resin, a fluorocarbon resin having a perfluorocarbon skeleton, such as a hydrocarbon resin such as an acrylic resin.
  • An ion exchange resin in which a cation exchange group (an exchange group in which the counter ion is a cation) such as a sulfonic acid group, a carboxylic acid group, or a phosphonic acid group is introduced into a polymer having a structure may be used without limitation. I'll do it.
  • anion exchange resin a polymer having a three-dimensional network structure similar to that of the cation exchange resin may be added to primary to tertiary amine groups, quaternary ammonia groups, and pyrzyl.
  • An ion exchange resin into which a cation exchange group (an exchange group in which the counter ion is an anion) such as a group, an imidazole group, a quaternary pyridinium group, or a quaternary imidazolium group can be used without limitation.
  • the constituent members are arranged and stacked, or are stored in the through-holes, and the proximal support 14, intermediate The support body 16 and the tip support body 18 are sequentially stacked, and these are adhered and fixed by the adhesive layers 16A and 14A. Further, the release liner 58 is attached to the tip support body 18 to complete the assembly.
  • a button battery or a thin battery disclosed in, for example, Japanese Patent Application Laid-Open No. 11 067236, US Patent Publication No. 2004Z0185667A1, US Patent No. 6855441, or the like can be used. It is not limited to the structure of this embodiment.
  • the working current collector 24A and the non-working current collector 44A were printed electrodes on which a PET material mixed with carbon and an adhesive was printed.
  • an activated carbon fiber layer composed of a circular carbon having a diameter of 17 mm and a thickness of 1. Omm was formed.
  • the activated carbon fiber layer was impregnated with a viscous liquid in which water, HPC, and hydrochloric acid were mixed to form a working side polarizable electrode 24B.
  • the activated carbon fiber layer was impregnated with a viscous liquid in which water, HPC, and NaCl were mixed to form the non-working side polarizable electrode 44B.
  • the weight of each was 120-125 mg.
  • the separator 26 was composed of a PP nonwoven fabric having a diameter of 18 mm and a thickness of 0.1 mm, and was impregnated with a viscous liquid obtained by mixing HPC and lidocaine hydrochloride in water.
  • the intermediate ion selective membrane 28 was a key-on exchange membrane having a diameter of 21 mm and a thickness of 30 m.
  • the chemical solution holding unit 30 was obtained by impregnating a PP nonwoven fabric having a thickness of 1. Omm and a diameter of 17 mm with a viscous liquid obtained by mixing water, HPC, and lidocaine hydrochloride, and the weight was 250 to 320 mg.
  • the working ion selective membrane 32 was a cation exchange membrane having a thickness of 30 ⁇ m and a diameter of 19 mm.
  • the area of the working ion selective membrane 32 is determined in consideration of the current value. For example, if the current value is 1 mA, a diameter 19 mm, the current density is 0. 35mAZcm 2.
  • a medicinal cation (lid power in) is substituted with an ion exchange group.
  • the electrode-side electrolyte holding part 46 in the non-working-side electrode structure 40 has a configuration in which a PP non-woven fabric is impregnated with the same viscous liquid containing NaCl as that used in the non-working-side polarizable electrode 44B, and has a diameter of 18 mm. The thickness was 100 m. Further, the tip side electrolyte solution holding part 48 is obtained by impregnating a PP non-woven fabric having a diameter of 17 mm and a thickness of 1 mm with the same viscous liquid as described above, and the weight is 250 to 320 mg.
  • the non-acting side ion selective membrane 50 is a key-on exchange membrane having a thickness of 30 m and a diameter of 21 mm, in which chloride ions are substituted with ion exchange groups.
  • the viscous liquid 70 is held in the sponges 64 and 66 provided in the recesses 60 and 62 of the release liner 58, so that the viscous liquid 70 is easily ionized. It can be attached to the selective membrane 32, 50. Therefore, when the iontophoresis device 10 is attached to the skin of a living body, the release liner 58 is peeled off so that a viscous liquid 70 is not formed between the ion selective membranes 32 and 50 and the skin as shown in FIG. A living body contact portion 72 is formed. Therefore, it is possible to easily attach a viscous liquid as compared with attaching a release liner by attaching a viscous liquid to an ion selective membrane.
  • the viscous liquid 70 improves the adhesion between the skin and the ion-selective membranes 32 and 50, can exhibit the performance of the ion-selective membrane, and sufficiently delivers the drug ions in the drug holding unit 30 to the skin. be able to.
  • the amount of the viscous liquid 70 adhering to the ion selective membranes 32 and 50 can be adjusted by adjusting the amount of the viscous liquid 70 to be immersed in the sponge.
  • the method of interposing the viscous liquid 70 is not limited to the above-described embodiment, and the V-deviation or one of the sponges 64, 66 can be omitted. Also, immediately before mounting on the living body, the mounting surface side of the iontophoresis device 10 is covered with the release liner 58, and the viscous liquid 70 is ionized. The biological contact portion 72 can also be formed by attaching the iontophoresis device 10 to the skin in a state of being attached to the attachment surface of the tophoresis device 10.
  • the viscous liquid 70 is soaked in the sponges 64 and 66, which are continuous foams, and covered with the release liner 58, so that the remaining amount can be controlled and drying during storage is prevented. it can. Further, since the sponges 64 and 66 are accommodated in the recesses 60 and 62, the viscous liquid 70 can be prevented from spreading too much, and a desired amount of viscous liquid per area can be secured. Furthermore, it does not adhere to unnecessary places and is easy to handle.
  • the force provided with the separator 26 prevents direct contact between the working polarizable electrode 24B and the intermediate ion-selective membrane 28. This is to prevent the occurrence of bubbles such as chlorine gas in the vicinity of the intermediate ion-selective membrane 28 and thereby impair the conductivity in the electrode structure, and direct contact can be prevented by other means. The case is not necessary. Even if the working side polarizable electrode 24B and the intermediate ion selective membrane 28 are in direct contact with each other, bubbles such as chlorine gas are not generated near the intermediate ion selective membrane 28 when energized. In some cases, no means for preventing direct contact between the two, such as separator 26, is required.
  • the electrode side electrolyte solution holding part 46 and the tip side electrolyte solution holding part 48 are common to the configuration in which a PP nonwoven fabric is impregnated with a viscous liquid containing an electrolyte solution. May be configured.
  • the present invention relates to a tomatophoresis system comprising an iontophoresis device for administering drug ions to a living body by applying a voltage, and more particularly, to the skin of an organism and the iontophoresis device ion. It is possible to provide an iontophoresis system that can easily improve the adhesion of a selective membrane and deliver drug ions evenly.

Abstract

Système d'ionophorèse (10) afin d'appliquer à la peau d'un organisme vivant, lequel système comprend une alimentation en courant continu (12), une structure d'électrode de côté actif (20) raccordée à l'une de l'anode et de la cathode de l'alimentation en courant continu, et une structure d'électrode de côté non actif (40) raccordée à l'autre, et qui administre à l'organisme vivant des ions médicamenteux se trouvant sur la structure d'électrode à côté actif en appliquant une tension générée par l'alimentation en courant continu, une couche détachable (58) pourvue de parties de retenue (éponges (64, 66) dans évidements (60, 62) de liquide visqueux (70) couvrant les côtés de l'organisme vivant de la membrane à sélectivité ionique (32) du côté actif et de la membrane à sélectivité ionique (50) du côté non actif du système d'ionophorèse (10) est employée. Par conséquent, l'adhérence entre la peau et les membranes à sélectivité ionique est augmentée simplement, et l'administration d'ions médicamenteux peut être accrue en exposant suffisamment les performances des membranes à sélectivité ionique.
PCT/JP2007/058362 2006-04-18 2007-04-17 Système d'ionophorèse WO2007123131A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008512122A JPWO2007123131A1 (ja) 2006-04-18 2007-04-17 イオントフォレーシスシステム

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-114553 2006-04-18
JP2006114553 2006-04-18

Publications (1)

Publication Number Publication Date
WO2007123131A1 true WO2007123131A1 (fr) 2007-11-01

Family

ID=38625031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/058362 WO2007123131A1 (fr) 2006-04-18 2007-04-17 Système d'ionophorèse

Country Status (2)

Country Link
JP (1) JPWO2007123131A1 (fr)
WO (1) WO2007123131A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037425A1 (fr) * 2001-10-31 2003-05-08 R & R Ventures Incorporation Dispositif d'ionophorese
JP2005319288A (ja) * 2004-04-07 2005-11-17 Vyteris Inc 長期保存性が改良された、電気的にアシストされたリドカインおよびエピネフリンのデリバリー装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037425A1 (fr) * 2001-10-31 2003-05-08 R & R Ventures Incorporation Dispositif d'ionophorese
JP2005319288A (ja) * 2004-04-07 2005-11-17 Vyteris Inc 長期保存性が改良された、電気的にアシストされたリドカインおよびエピネフリンのデリバリー装置

Also Published As

Publication number Publication date
JPWO2007123131A1 (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
US8386030B2 (en) Iontophoresis device
EP0754078B1 (fr) Systeme d'electrotransport a systeme de liberation de medicament ameliore
US6289242B1 (en) Electrotransport system with ion exchange material competitive ion capture
US20060129085A1 (en) Iontophoresis device
EP1872799A1 (fr) Preparation externe, procede d application de preparation externe, dispositif d iontophorese et timbre transdermique
WO2007111368A1 (fr) Appareil iontophorétique
JP2007282900A (ja) イオントフォレーシス装置
JP2007289482A (ja) 経皮投与装置
WO2007123131A1 (fr) Système d'ionophorèse
WO2008026364A1 (fr) Dispositif d'ionophorèse
JP4805693B2 (ja) イオントフォレーシス装置及びその製造方法
JP2007260082A (ja) イオントフォレーシス装置
JP2007268135A (ja) イオントフォレーシス装置
JP2007260107A (ja) イオントフォレーシス装置
JP2007244551A (ja) イオントフォレーシス装置
JP2009034117A (ja) イオントフォレーシス装置
JP2008167995A (ja) 印刷電極部材およびイオントフォレーシス装置
WO2007119581A1 (fr) Structure d'electrode d'utilisation de dispositif d'ionophorese
JPWO2007123142A1 (ja) イオントフォレーシス装置
JP2008110056A (ja) 電極部材および電極部材を含むイオントフォレーシス装置
JP2007020892A (ja) イオントフォレーシス装置
JP2007135814A (ja) 薬物イオン投与方法及びピン型イオントフォレーシス装置
JP2007268194A (ja) イオントフォレーシス装置
JP2007244699A (ja) イオントフォレーシス装置
JP2007167132A (ja) イオントフォレーシス装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07741798

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008512122

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07741798

Country of ref document: EP

Kind code of ref document: A1